Search for 'an,phr: 303'

ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.

By García Carbonero, Rocío . Neuroendocrinology, 2016 . 103(2):186-94. , Formato Vancouver: GarcíaCarbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B et al; Vienna Consensus Conference participants. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology. 2016;103(2):186-94.

Place Hold on ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.

Deep sequencing reveals microRNAs predictive of antiangiogenic drug response.

By Castellano, Daniel. JCI insight, 2016 . 1(10):e86051. , Formato Vancouver: García Donas J, Beuselinck B, Inglada Pérez L, Graña O, Schöffski P, Wozniak A et al. Deep sequencing reveals microRNAs predictive of antiangiogenic drug response. JCI Insight. 2016 Jul 7;1(10):e86051.

Place Hold on Deep sequencing reveals microRNAs predictive of antiangiogenic drug response.

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

By Paz-Ares Rodríguez, Luis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2016 . 27(3):423-9. , Formato Vancouver: Ramalingam SS, O'Byrne K, Boyer M, Mok T, Jänne PA, Zhang H et al. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Ann Oncol. 2016 Mar;27(3):423-9.

Place Hold on Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer.

By Riesco Martínez, María C. Journal of oncology practice, 2016 . 12(6):e710-23. , Formato Vancouver: Riesco Martínez MC, Berry SR, Ko YJ, Mittmann N, Giotis A, Lien K et al. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. J Oncol Pract. 2016 Jun;12(6):e710-23.

Place Hold on Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer.

Current Challenges in Cancer Treatment.

By Zugazagoitia, Jon | Guedes, Cristiano | Ponce Aix, Santiago | Ferrer, Irene | Molina Pinelo, Sonia | Paz-Ares Rodríguez, Luis. Clinical therapeutics, 2016 . 38(7):1551-66. , Formato Vancouver: Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina Pinelo S, Paz Ares L. Current Challenges in Cancer Treatment. Clin Ther. 2016 Jul;38(7):1551-66.

Place Hold on Current Challenges in Cancer Treatment.

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.

By Paz-Ares Rodríguez, Luis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2016 . 27(8):1573-9. , Formato Vancouver: Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Kurek R et al. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. Ann Oncol. 2016 Aug;27(8):1573-9.

Place Hold on Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.

Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases.

By Rojas Laimito, Katerin | Sepúlveda Sánchez, Juan Manuel | Manso Sánchez, Luis | Pascual, Tomás | Ciruelos Gil, Eva María. Ecancermedicalscience, 2016 . 10:632. , Formato Vancouver: Laimito KR, Gámez Pozo A, Sepúlveda J, Manso L, López Vacas R, Pascual T et al. Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases. Ecancermedicalscience. 2016 Apr 11;10:632.

Place Hold on Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases.

Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.

By Rodríguez Garzotto, Analía | Díaz García, C. Vanesa | Agudo López, Alba | Prieto García, Elena | Ponce Aix, Santiago | López Martín, José Antonio | Paz-Ares Rodríguez, Luis | Iglesias Docampo, Lara | Agulló Ortuño, María Teresa. Medical oncology (Northwood, London, England), 2016 . 33(10):105. , Formato Vancouver: Rodríguez Garzotto A, Díaz García CV, Agudo López A, Prieto García E, Ponce S, López Martín JA et al. Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer. Med Oncol. 2016 Oct;33(10):105.

Place Hold on Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.

Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.

By Sepúlveda Sánchez, Juan Manuel. Journal of neuro-oncology, 2016 . 127(3):569-79. , Formato Vancouver: Balana C, De Las Penas R, Sepúlveda JM, Gil Gil MJ, Luque R, Gallego O et al. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. J Neurooncol. 2016 May;127(3):569-79.

Place Hold on Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

By Castellano, Daniel. Lancet (London, England), 2016 . 387(10031):1909-20. , Formato Vancouver: Rosenberg JE, Hoffman Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7;387(10031):1909-20.

Place Hold on Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.

By Molina Pinelo, Sonia | Paz-Ares Rodríguez, Luis. Oncotarget, 2016 . 7(33):52849-52861. , Formato Vancouver: Usó M, Jantus Lewintre E, Bremnes RM, Calabuig S, Blasco A, Pastor E et al. Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers. Oncotarget. 2016 Aug 16;7(33):52849-52861.

Place Hold on Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.

Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

By Ponce Aix, Santiago | Zugazagoitia, Jon | Enguita Valls, Ana Belén. Lung cancer : journal of the International Association for the Study of Lung Cancer, 2016 . 96:1-6. , Formato Vancouver: Cedrés S, Ponce Aix S, Pardo Aranda N, Navarro Mendivil A, Martinez Marti A, Zugazagoitia J et al. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). Lung Cancer. 2016 Jun;96:1-6.

Place Hold on Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

By Paz-Ares Rodríguez, Luis. The Lancet. Oncology, 2016 . 17(5):577-89. , Formato Vancouver: Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 May;17(5):577-89.

Place Hold on Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.

By Grávalos Castro, Cristina. Targeted oncology, 2016 . 11(3):383-400. , Formato Vancouver: Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R et al. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol. 2016 Jun;11(3):383-400.

Place Hold on Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

By Ciruelos Gil, Eva María. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016 . 34(14):1601-10. , Formato Vancouver: Ribi K, Luo W, Bernhard J, Francis PA, Burstein HJ, Ciruelos E et al. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016 May 10;34(14):1601-10.

Place Hold on Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

A unique case of distant skin metastasis from chondroid chordoma.

By Riesco Martínez, María C | Parrilla Rubio, Lucía | Enguita Valls, Ana Belén | Delgado Márquez, Ana María | López Martín, José Antonio. JAAD case reports, 2016 . 2(1):63-6. , Formato Vancouver: Riesco Martínez MC, Parrilla Rubio L, Enguita Valls AB, Delgado Márquez AM, Ruste SA, López Martín JA. A unique case of distant skin metastasis from chondroid chordoma. JAAD Case Rep. 2016 Feb 3;2(1):63-6.

Place Hold on A unique case of distant skin metastasis from chondroid chordoma.

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.

By Sepúlveda Sánchez, Juan Manuel. Neuro-oncology, 2016 . 18(8):1146-56. , Formato Vancouver: Brandes AA, Carpentier AF, Kesari S, Sepulveda Sánchez JM, Wheeler HR, Chinot O et al. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro Oncol. 2016 Aug;18(8):1146-56.

Place Hold on A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.

Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.

By Grávalos Castro, Cristina. Oncotarget, 2015 . 6(8):6422-30. , Formato Vancouver: García González X, Cortejoso L, García MI, García Alfonso P, Robles L, Grávalos C et al. Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer. Oncotarget. 2015 Mar 20;6(8):6422-30.

Place Hold on Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.

Use of bevacizumab as a first-line treatment for metastatic breast cancer.

By Manso Sánchez, Luis. Current oncology (Toronto, Ont.), 2015 . 22(2):e51-60. , Formato Vancouver: Manso L, Moreno F, Márquez R, Castelo B, Arcediano A, Arroyo M et al. Use of bevacizumab as a first-line treatment for metastatic breast cancer. Curr Oncol. 2015 Apr;22(2):e51-60.

Place Hold on Use of bevacizumab as a first-line treatment for metastatic breast cancer.

Trypanocidal, trichomonacidal and cytotoxic components of cultivated Artemisia absinthium Linnaeus (Asteraceae) essential oil.

By Agulló Ortuño, María Teresa. Memórias do Instituto Oswaldo Cruz, 2015 . 110(5):693-9. , Formato Vancouver. Martínez Díaz RA, Ibáñez Escribano A, Burillo J, Heras Lde L, Prado GD, Agulló Ortuño MT et al. Trypanocidal, trichomonacidal and cytotoxic components of cultivated Artemisia absinthium Linnaeus (Asteraceae) essential oil. Mem Inst Oswaldo Cruz. 2015 Aug;110(5):693-9.

Place Hold on Trypanocidal, trichomonacidal and cytotoxic components of cultivated Artemisia absinthium Linnaeus (Asteraceae) essential oil.

The need for post-mastectomy radiotherapy in patients with IBC.

By Ruiz Ares, Gustavo | Ciruelos Gil, Eva María | Manso Sánchez, Luis. Nature reviews. Clinical oncology, 2015 . 12(6):370. , Formato Vancouver: Ares GR, Ciruelos E, Manso L. The need for post-mastectomy radiotherapy in patients with IBC. Nat Rev Clin Oncol. 2015 Jun;12(6):370.

Place Hold on The need for post-mastectomy radiotherapy in patients with IBC.

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.

By Manso Sánchez, Luis. Breast cancer research and treatment, 2015 . 154(2):351-7. , Formato Vancouver: Llombart Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J et al. SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015 Nov;154(2):351-7.

Place Hold on SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015.

By García Carbonero, Rocío . Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015 . 17(12):972-81. , Formato Vancouver: Aranda E, Aparicio J, Alonso V, García Albeniz X, García Alfonso P, Salazar R et al. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015. Clin Transl Oncol. 2015 Dec;17(12):972-81.

Place Hold on SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015.

SEOM clinical guidelines in early-stage breast cancer 2015.

By Ciruelos Gil, Eva María. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015 . 17(12):939-45. , Formato Vancouver: García Sáenz JA, Bermejo B, Estevez LG, Palomo AG, González Farre X, Margeli M et al. SEOM clinical guidelines in early-stage breast cancer 2015. Clin Transl Oncol. 2015 Dec;17(12):939-45.

Place Hold on SEOM clinical guidelines in early-stage breast cancer 2015.

SEOM guidelines for the management of Malignant Melanoma 2015.

By Martín, J.A.L.. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015 . 17(12):1030-5. , Formato Vancouver: Berrocal A, Arance A, Espinosa E, Castaño AG, Cao MG, Larriba J et al. SEOM guidelines for the management of Malignant Melanoma 2015. Clin Transl Oncol. 2015 Dec;17(12):1030-5.

Place Hold on SEOM guidelines for the management of Malignant Melanoma 2015.

Seom guidelines for the treatment of gastric cancer 2015.

By Grávalos Castro, Cristina. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015 . 17(12):996-1004. , Formato Vancouver: Martin Richard M, Custodio A, García Girón C, Grávalos C, Gómez C, Jiménez Fonseca P et al. Seom guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol. 2015 Dec;17(12):996-1004.

Place Hold on Seom guidelines for the treatment of gastric cancer 2015.

Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literature.

By De Velasco, Guillermo | Muñoz, César | Sepúlveda Sánchez, Juan Manuel | Castellano, Daniel. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015 . 9(3-4):E243-6. , Formato Vancouver: de Velasco G, Munoz C, Sepulveda JM, Castellano D. Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literature. Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E243-6.

Place Hold on Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literature.

Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.

By Grávalos Castro, Cristina. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2015 . ;26(3):535-41. , Formato Vancouver: Sotelo MJ, Sastre J, Maestro ML, Veganzones S, Viéitez JM, Alonso V et al. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer. Ann Oncol. 2015 Mar;26(3):535-41.

Place Hold on Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.

Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.

By Agulló Ortuño, María Teresa | Díaz García, C. Vanesa | Agudo López, Alba | Pérez, Carlos | Cortijo, Ana | Paz-Ares Rodríguez, Luis | Pozo Rodríguez, Francisco | Cortés-Funes Castro, Hernán | López Martín, José Antonio. Journal of cancer research and clinical oncology, 2015 . 141(1):43-53. , Formato Vancouver: Agulló Ortuño MT, Díaz García CV, Agudo López A, Pérez C, Cortijo A, Paz Ares L et al. Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer. J Cancer Res Clin Oncol. 2015 Jan;141(1):43-53.

Place Hold on Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.

Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer.

By Manso Sánchez, Luis. Current medical research and opinion, 2015 . 31(6):1129-37. , Formato Vancouver: Martín M, González Rivera M, Morales S, de la Haba Rodríguez J, González Cortijo L, Manso et al. Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer. Curr Med Res Opin. 2015 Jun;31(6):1129-37.

Place Hold on Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer.

Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.

By Grávalos Castro, Cristina. Molecular diagnosis & therapy, 2015 . 19(6):397-408. , Formato Vancouver: Llovet P, Sastre J, Ortega JS, Bando I, Ferrer M, García Alfonso P et al. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy. Mol Diagn Ther. 2015 Dec;19(6):397-408.

Place Hold on Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.

Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.

By Díaz García, C. Vanesa | Agudo López, Alba | Pérez, Carlos | Prieto García, Elena | Iglesias Docampo, Lara | Ponce Aix, Santiago | Rodríguez Garzotto, Analía | Rodríguez Peralto, José Luis | Cortés-Funes Castro, Hernán | López Martín, José Antonio | Agulló Ortuño, María Teresa. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015 . 36(2):1199-206. , Formato Vancouver: Díaz García CV, Agudo López A, Pérez C, Prieto García E, Iglesias L, Ponce S et al. Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer. Tumour Biol. 2015 Feb;36(2):1199-206.

Place Hold on Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.

PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.

By Villacampa Aubá, Felipe | Duarte Ojeda, José Manuel | Martínez, Victor | Gómez Rodríguez, María José | Martín, María Luisa | Fernández, Manoli | Castellano, Daniel | Rodríguez Peralto, José Luis | Rosa Kehrman, Federico de la . Molecular carcinogenesis, 2015 . 54(7):566-76. , Formato Vancouver: Dueñas M, Martínez Fernández M, García Escudero R, Villacampa F, Marqués M, Saiz Ladera C et al. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors. Mol Carcinog. 2015 Jul;54(7):566-76.

Place Hold on PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.

By Sepúlveda Sánchez, Juan Manuel. Investigational new drugs, 2015 . 33(2):357-70. , Formato Vancouver: Rodón J, Carducci M, Sepulveda Sánchez JM, Azaro A, Calvo E, Seoane J et al. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs. 2015 Apr;33(2):357-70.

Place Hold on Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.

Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.

By Ciruelos Gil, Eva María. Breast cancer research and treatment, 2015 . 149(1):151-61. , Formato Vancouver: Tolaney S, Burris H, Gartner E, Mayer IA, Saura C, Maurer M et al. Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2015 Jan;149(1):151-61.

Place Hold on Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

By Ciruelos Gil, Eva María. The New England journal of medicine, 2015 . 372(8):724-34. , Formato Vancouver: Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M et al; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015 Feb 19;372(8):724-34.

Place Hold on Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

By Castellano, Daniel. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2015 . 26(9):1987-93. , Formato Vancouver: Grande E, Capdevila J, Castellano D, Teulé A, Durán I, Fuster J et al. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann Oncol. 2015 Sep; 26(9):1987-93.

Place Hold on Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.

By Manso Sánchez, Luis. Breast cancer research and treatment, 2015 . 151(3):597-606. , Formato Vancouver: Gil Gil MJ, Bellet M, Morales S, Ojeda B, Manso L, Mesia C et al. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. Breast Cancer Res Treat. 2015 Jun;151(3):597-606.

Place Hold on Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.

Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology.

By Grávalos Castro, Cristina. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015 . 17(10):763-71. , Formato Vancouver: Goday A, Barneto I, García Almeida JM, Blasco A, Lecube A, Grávalos C et al. Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2015 Oct;17(10):763-71.

Place Hold on Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology.

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.

By Castellano, Daniel. Cancer, 2020 . 126(18):4156-4167. , Formato Vancouver: Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020 Sep 15;126(18):4156-4167.

Place Hold on Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

By Castellano, Daniel. The New England journal of medicine, 2015 . 373(19):1803-13. , Formato Vancouver: Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S et al; CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1803-13.

Place Hold on Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

By Paz-Ares Rodríguez, Luis. The Lancet. Oncology, 2015 . 16(3):328-37. , Formato Vancouver: Paz Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M et al; INSPIRE investigators. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol. 2015 Mar;16(3):328-37.

Place Hold on Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

Mammographic density and breast cancer in women from high risk families.

By Robles Díaz, Luis. Brest cancer research: BCR, 2015 . 17(1):93. , Formato Vancouver: Ramón y Cajal T, Chirivella I, Miranda J, Teule A, Izquierdo Á, Balmaña J et al. Mammographic density and breast cancer in women from high risk families. Breast Cancer Res. 2015 Jul 11;17(1):93.

Place Hold on Mammographic density and breast cancer in women from high risk families.

Manejo de la enfermedad tromboembólica venosa en pacientes oncológicos: guías de práctica clínica española. Consenso SEACV-SEOM,

By Iglesias Docampo, Lara. Medicina clínica, 2015 . 144 Suppl 1:3-15. , Formato Vancouver: Olmos VP, Ramos Gallo MJ, Rebollo MA, Ortega DB, Docampo LI, Romera Villegas A et al; Sociedad Española de Oncología Médica (SEOM); Sociedad Española de Angiología y Cirugía Vascular (SEACV). Manejo de la enfermedad tromboembólica venosa en pacientes oncológicos: guías de práctica clínica española. Consenso SEACV-SEOM. Med Clin (Barc). 2015 Jan;144 Suppl 1:3-15.

Place Hold on Manejo de la enfermedad tromboembólica venosa en pacientes oncológicos: guías de práctica clínica española. Consenso SEACV-SEOM,

Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development.

By García Carbonero, Rocío . Cancer metastasis reviews, 2015 . 34(4):823-42. , Formato Vancouver: García Carbonero R, García Figueiras R, Carmona Bayonas A, Sevilla I, Teule A, Quindos M et al; Spanish Cooperative Group of Neuroendocrine Tumors (GETNE). Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev. 2015 Dec;34(4):823-42.

Place Hold on Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development.

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.

By Ponce Aix, Santiago. The Lancet. Oncology, 2015 . 16(8):990-8. , Formato Vancouver: Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015 Aug;16(8):990-8.

Place Hold on Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.

By Sepúlveda Sánchez, Juan Manuel. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015 . 21(3):553-60. , Formato Vancouver: Rodon J, Carducci MA, Sepulveda Sánchez JM, Azaro A, Calvo E, Seoane J et al. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin Cancer Res. 2015 Feb 1;21(3):553-60.

Place Hold on First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.

First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours.

By Grávalos Castro, Cristina. European journal of cancer (Oxford, England: 1990), 2015 . 51(11):1371-80. , Formato Vancouver: Sastre J, Massuti B, Pulido G, Guillén Ponce C, Benavides M, Manzano JL; Spanish Cooperative Group for the Treatment of Digestive Tumours TTD. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. Eur J Cancer. 2015 Jul;51(11):1371-80.

Place Hold on First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours.

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.

By Cortés-Funes Castro, Hernán. European journal of cancer (Oxford, England :1990), 2015 . 51(12):1481-9. , Formato Vancouver: Sonnenblick A, Francis PA, Azim HA Jr, de Azambuja E, Nordenskjöld B, Gutiérez J et al. Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. Eur J Cancer. 2015 Aug;51(12):1481-9.

Place Hold on Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

By Castellano, Daniel. British journal of cancer, 2015 . 113(1):12-9. , Formato Vancouver: Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer. 2015 Jun 30;113(1):12-9.

Place Hold on Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.